Shanghai, China and New Jersey, U.S., Aug 21, 2023 — Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company dedicated to bringing novel therapies to cancer and liver fibrosis patients worldwide, is pleased to announce that it has been included as a constituent stock in the Hong Kong Hang Seng Composite Index, effective September 4, 2023 (Monday). The inclusion in the index allows Laekna, Inc. to be eligible for trading through Shanghai and Shenzhen Stock Connect, in accordance with the applicable regulations.

As a constituent stock of the Hang Seng Composite Index, Laekna, Inc. fulfills the core requirements for being included in the list of stocks eligible for trading under Stock Connect. Its official addition to the list is expected following the adjustments to the Hang Seng Composite Index constituents on September 4, 2023.

This step will allow qualified mainland China investors to access the company’s stock through Stock Connect then.

—End—

For more information, please visit:

https://www.laekna.com/

or https://www.linkedin.com/company/74110713/

Contact us

IR

ir@laekna.com

Media

communication@laekna.com

Corporate and Business Development

BD@laekna.com